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Abstract: Objective. To evaluate clinical and antibiotic resistance impact of carbapenems stewardship
programs. Methods: descriptive study, pre-post-intervention, between January 2012 and December
2019; 350-bed teaching hospital. Prospective audit and feedback to prescribers was carried out
between January 2015 and December 2019. We evaluate adequacy of carbapenems prescription to
local guidelines and compare results between cases with accepted or rejected intervention. Analysis
of antibiotic-consumption and hospital-acquired multidrug-resistant (MDR) bloodstream infections
(BSIs) was performed. Results: 1432 patients were followed. Adequacy of carbapenems prescription
improved from 49.7% in 2015 to 80.9% in 2019 (p < 0.001). Interventions on prescription were
performed in 448 (31.3%) patients without carbapenem-justified treatment, in 371 intervention was
accepted, in 77 it was not. Intervention acceptance was associated with shorter duration of all
antibiotic treatment and inpatient days (p < 0.05), without differences in outcome. During the period
2015–2019, compared with 2012–2014, decreased meropenem consumption (Rate Ratio 0.58; 95%CI:
0.55–0.63), candidemia and hospital-acquired MDR BSIs rate (RR 0.62; 95%CI: 0.41–0.92, p = 0.02),
and increased cefepime (RR 2; 95%CI: 1.77–2.26) and piperacillin-tazobactam consumption (RR 1.17;
95%CI: 1.11–1.24), p < 0.001. Conclusions: the decrease and better use of carbapenems achieved could
have clinical and ecological impact over five years, reduce inpatient days, hospital-acquired MDR
BSIs, and candidemia, despite the increase in other antibiotic-consumption.
Keywords: antimicrobial stewardship; multidrug-resistant; hospital infections; bloodstream infec-
tions; carbapenems; candidemia
1. Introduction
Antimicrobial resistance is a threat to global public health and many countries reaffirm
their commitment to develop national action plans to deal with the problem, establishing,
among other measures, systems to guarantee a more appropriate use of antibiotics [1].
Antimicrobial overuse and inappropriate use remain significant problems and, al-
though the highest consumption of antibiotics is at the outpatient level, most studies on the
impact of antimicrobial stewardship programs (ASP) focused on the hospital setting, where
patients are subjected to a higher pressure of antibiotic treatment and there is a greater risk
of transmission of resistance.
Antimicrobial stewardship are quality improvement programs that include hetero-
geneous interventions [2]. The implementation of these ASP has shown a significant
reduction of antibiotic use and hospital costs [3], but few studies refer to the impact on clin-
ical outcome [4], antibiotic resistance [5,6], or incidence of Clostridioides difficile infection [7].
Interventions are generally more effective in prospective studies with clinical feedback
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on prescribing, but there are few studies of this type that cover the entire hospital with a
duration long enough in time to evaluate the persistence of their effect [8,9].
The first steps toward ASP in an organization are to identify a leader or leaders for
the program and to allocate sufficient administrative support for the ASP [10]. Limited
resources for the antimicrobial stewardship implementation make necessary prioritizing
those interventions that might have greater impact. Any antibiotic can have a potential
effect on the development of bacterial resistance, but that effect and the persistence of
resistance over time depends on the type of antibiotic and bacterial species, which may be
more or less easy to develop resistance, and may have different rates of transmission of
resistance [11–13]. In addition to the impact on bacterial resistance, different antimicrobial
agents have a different impact on the human gastrointestinal colonization by the Candida
species, depending on the pharmacological and antibacterial properties of each drug. It
has been demonstrated in the murine model that carbapenems cause high increase of yeast
counts in the gastrointestinal tract [14], and the use of carbapenems in the treatment of
hospitalized patients is associated with the development of candidemia [15].
The increasing number of infections caused by extended spectrum ß-lactamase (ESBL)
producing Enterobacteriaceae has led to an increase in carbapenems consumption, and the
appearance and spread of carbapenem-resistant enterobacteriaceae, causing infections with
high mortality due to the shortage of treatment alternatives [16].
Carbapenem-resistant enterobacteriaceae rank among the top three multidrug-resistant
pathogens on the World Health Organization (WHO)’s priority list [17]. The aim of the
study is to evaluate the clinical and antibiotic resistance impact of carbapenems stew-
ardship implementation over 5 years. This manuscript is an extension of a previously
published partial one [18], expanding the analysis to all carbapenems and adding years
of study.
2. Results
2.1. Adequacy of Treatment
Between 2015 and2019, 1432 patients received treatment with carbapenems (1280
meropenem and 152 ertapenem). The indication of justified treatment with carbapenems
progressively improved over time from 49.7% in 2015 to 80.9% in 2019, p <0.001.
2.2. Clinical Impact
Between 2015 and 2019, 1432 patients received treatment with carbapenems, of which
920 were male and 512 female; age 69.7 ± 15.2 years (range 1–97 years). The sites of
infection were: urinary 518 (36.2%), abdominal 408 (28.5%), pulmonary 315 (22%), skin and
soft tissue 60 (4.2%), febrile neutropenia 31 (2.2%), intravascular catheter 28 (1.9%), other
72 (5%). Place of infection acquisition: hospital-acquired 635 (44.3%), healthcare-associated
559 (39%), and community-associated 238 (16.6%).
Out of the 1432 patients who received treatment with carbapenems, in 984 (68.7%)
of them the treatment was considered justified; in 448 (31.3%) the treatment was not
considered justified and interventions were performed with a suggestion for appropriate
treatment: in 371 (83%), the intervention was accepted, and in 77 it was not.
The clinical characteristics of patients were similar between patients with and without
acceptance of ASP recommendations, although the degree of intervention acceptance
varied according to prescriber (between 29% and 100%) and infection localization (Table 1).
There were no significant differences between cases with accepted intervention and
cases with rejected intervention in clinical outcome or collateral damage. The acceptance of
the intervention was associated with shorter duration inpatient days (p < 0.05), and less
development of yeast colonization or infection, but not statistically significant (Table 2).
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Table 1. Baseline demographic and clinical characteristics of patients with and without acceptance of
ASP Recommendations. Years 2015–2019.
Variables InterventionAccepted n = 371
Intervention
Rejected n = 77 p
Male gender, n (%) 243 (65.5) 48 (62.3) 0.6
Median age ± SD, years (range) 67.2 ± 15.5 (10–96) 66 ± 18.8 (6–95) 0.6
Charlson comorbidity score,
Median ± SD, (range) 5.2 ± 2.9 (0–13.6) 4.8 ± 2.9 (0–12) 0.4
Neutropenia, <500/mL 7 (1.9) 3 (3.9) 0.4
Sepsis 15 (4) 5 (6.5) 0.4
Site of infections, n (%)
Pulmonary 64 (17.3) 24 (31.2) 0.007
Abdominal 99 (26.7) 36 (46.8) 0.001
Skin/soft tissue 25 (6.7) 1 (1.3) 0.06
Urinary 131 (35.3) 12 (15.6) 0.001
Other 52 (14) 4 (5.2) 0.04
Acquisition place of infection
Hospital onset 127 (34.2) 33 (42.8) 0.15
Healthcare-associated 134 (36.1) 28 (36.4) 1
Community-associated 110 (29.6) 16 (20.8) 0.13
Table 2. Clinical results of patients with and without Acceptance of ASP recommendations. Years
2015–2019.
Variables InterventionAccepted n = 371
Intervention
Rejected n = 77 p
Evolution to healing 329 (88.7%) 64 (83.1%) 0.4
Death caused by infection 15 (4%) 7 (9.1%) 0.08
All-cause crude death 42 (11.3%) 12 (15.6%) 0.3
Readmission in a month 15 # (4%) 4 * (5.2%) 0.6
Adverse effects 42 (11.3%) 7 (9.1%) 0.8
Phlebitis 64 (17.3%) 11 (14.3%) 0.6
Development of resistance to
treatment 8 (2.2%) 0 (0%) 0.4
Diarrhea caused by C. difficile 6 (1.6%) 2 (2.6%) 0.6
Colonization-Infection with
Candida spp. 40 (10.8%) 11 (14.3%) 0.4
Days of antibiotic treatment
(intervention series) 11 ± 10.2 12.7 ± 8.5 0.2
Total inpatient days, X ± SD 17.7 ± 16.7 25.3 ± 22.3 0.006
Inpatient days
post-intervention, X ± SD 12.5 ± 14.2 16.7 ± 18.9 0.03
# 9 relapses of the infection, 6 due to other causes. * No relapse of infection due to other cause.
The Charlson index was similar throughout the intervention period (5.4 in 2015 vs.
5.8 in 2019, p = 0.07) and was higher in patients who died: 7.1 ± 2.3 vs. 5.3 ± 2.6, p < 0.001.
The duration of all antibiotic treatment along the series decreased significantly from 2015
(12.8 ± 11.3 days) to 2019 (10.8 ± 10.1), p = 0.03.
Coinciding with the start-up of ASP, a significant change point was observed in 2014
in the trend analysis of meropenem consumption, in the period 2012–2014, meropenem
consumption decreased −0.08% per year (95%CI: −29.4 to 41.5) and in 2014–2019 decreased
−15.5% per year (95%CI: −26.2 to −3.3). There was a 42% decrease in the consumption of
meropenem during the intervention period with respect to the years 2012–2014 (Rate Ratio
0.58; 95%CI: 0.5–0.6); and increased consumption of ertapenem (RR 1.2; 95%CI 1.1–1.3)
(Figure 1).
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2.3. Impact on Resistance
The evolution of total consumption and by class of antibiotics is shown in Figure 2.
Total consumption did not decrease and the consumption of antibiotics used as an alter-
native to carbapenem treatment increased: cefepime (RR 2; 95%CI: 1.8–2.3) (11.7 defined
daily doses (DDD)/1000 occupied bed days (OBDs) in 2012–2014 vs. 18.5 in 2015–2019),
piperacillin-tazobactam (RR 1.17; 95%CI: 1.1–1.24) (54.4 DDD/1000 OBDs in 2012–2014
vs. 63.8 in 2015–2019), aminoglycosides (RR 1.2; 95%CI: 1.1–1.3 (30.2 DDD/1000 OBDs in
2012–2014 vs. 36.2 in 2015–2019), and third-generation cephalosporins (59.4 DDD/1000
OBDs in 2012–2014 vs. 66.6 in 2015–2019), p < 0.001. Ciprofloxacin and metronidazole
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consumption remained similar, ciprofloxacin (88.5 in 2015–2019 vs. 89.8 DDD/1000 OBDs
in 2012–2014), metronidazole (30.5 in 2015–2019 vs. 32.5 DDD/1000 OBDs in 2012–2014).
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Figure 2. Evolution of antibiotic consu ption bet een the years 2012 to 2019.
lobal incidence of bacteremi adjusted by 1 00 OBDs incr ased by 5.6% during
the period 2015–2019 vs. 201 –2014. The incidence density candide ia and hospital-
cquired multidrug-resistant (MDR) bloodstream infections (BSIs) decreased after ASP
start-up in a matching with decreas in carbapenem consumption (Figures 1 and 3). In 2015–
2019 candidemia and hospital-acquired MDR BSIs rate was 0.08/10 0 OBDs vs. 0.13 in
2012–2014 (RR 0.6; 95%CI: 0.4–0.9, p = 0.02) (candidemia RR 0.56, 95%CI: 0.3–1. 4; MDR
BSIs RR 0.7; 95%CI: 0.4–1.1). Conversely, the incidence density of hospital-acquired BSIs
caused by non-MDR strains of the same microorganisms under study increased 25% during
the intervention period (RR 1.2; 95%CI: 1.08–1.4, p = 0.03).
Patients ith hospital-acquired candide ia and MDR BSIs had higher 30-day all-
cause mortality than patients with non-MDR BSIs: 28.3% vs. 18.7%, p = 0.04. The incidence
density of 30-day all-cause mortality for hospital-acquired candidemia and MDR BSIs
decreased during the intervention period by 49%, without reaching statistical significance
(0.02/1000 OBDs in 2015–2019 vs. 0.04 in 2012–2014; RR 0.61; 95%CI: 0.3–1.3). 30-day all-
cause mortality rate for hospital-acquired bacteremia caused by non-MDR microorganisms
increased over time, without statistical significance: 0.12/1000 patients-days in 2012–2014
to 0.14 in 2015–2019 (RR 1.15; 95%CI: 0.8–1.7).
Throughout the study period, neither carbapenemase-producing microorganisms nor
Vancomycin-resistant Enterococcus spp. were observed in hospital-acquired bacteremia,
and the incidence of Clostridioides difficile-associated diarrhea remained stable (0.20/1000
OBDs in 2015 to 0.15 in 2019; RR 0.71, 95%CI: 0.4–1.1), p = 0.19. The resistance to piperacillin-
tazobactam, cefepime, and aminoglycosides in Klebsiella pneumoniae and Pseudomonas
aeruginosa isolated in blood cultures did not change significantly during the intervention
period. Resistance to piperacillin–tazobactam in Klebsiella pneumoniae 8.4 ± 9.2 in 2012–2104
vs. 11 ± 6.8 in 2015–2019 and in Pseudomonas aeruginosa 16.6 ± 9.3 in 2012–2104 vs. 12.7 ±
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12.1 in 2015–2019. Resistance to cefepime in Klebsiella pneumoniae 11.5 ± 6.8 in 2012–2104 vs.
6.7 ± 4.7 in 2015–2019 and in Pseudomonas aeruginosa 16.6 ± 9.3 in 2012–2104 vs. 12.7 ± 12.1
in 2015–2019. Resistance to gentamicin in Klebsiella pneumoniae 4.4 ± 6 in 2012–2104 vs. 6.9
± 4.9 in 2015–2019 and resistance in Pseudomonas aeruginosa to tobramycin 17.9 ± 14.2 in
2012–2104 vs. 3.6 ± 4.9 in 2015–2019 and to amikacin 0% throughout the 2012–2019 period.
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decreased by 18% (0 27.6 in 2015–2019 vs. 32.8 DDD/1000 OBDs in 2012–2014; RR 0.82;
95%CI: 0.76–0.88, p < 0.001), Table 3.
Table 3. Potential Changes in Healthcare during the Study Period by Year.
Healthcare Variable. 2012 2013 2014 2015 2016 2017 2018 2019
Nº of patients admitted 14,721 14,615 14,979 14,867 14,852 15,248 15,561 15,641
Nº of inpatient days 119,885 121,181 119,615 116,588 114,072 114,864 120,133 119,350
Blood cultures performed, No. 3242 3340 2985 3003 3419 3074 3554 3331
Nº blood cultures/1000 OBDs * 27.0 27.6 24.9 25.8 29.9 26.8 29.6 27.9
Hospital-acquired BSIs per 1000 OBDs * 0.8 0.9 0.8 0.8 0.8 1.0 1.4 1.0
Hospital-acquired no-MDR
BSIs/1000 OBDs * 0.7 0.8 0.7 0.7 0.8 0.9 1.3 0.9
Intravascular catheter-associated
BSIs/1000 OBDs * 0.3 0.4 0.5 0.4 0.4 0.5 0.7 0.4
Surgical procedures, Nº/1000 OBDs *. 74 77 74 78 82 80 76 79
Case mix index + 1.5 1.5 1.6 1.6 0.8 0.9 0.9 0.9
Parenteral nutrition units,
No./1000 OBDs 29.1 38.7 39.5 46.1 41.3 34.0 28.9 26.5
Consumption of antifungals,
DDD/1000 OBDs * 29.1 38.4 30.8 34.9 33.1 25.5 23.6 21.1
MDR: multidrug-resistant. BSIs: bloodstream infections. OBDs: occupied bed days. * In the period 2015–2019 compared to 2012–2014
increased the number of blood cultures performed, hospital-acquired BSIs and hospital-acquired no-MDR BSIs, catheter-associated BSIs
and surgical procedures; antifungal consumption decreased (p < 0.001). + The calculation system was modified after 2015 (Ref. [19]), case
mix index increased progressively between 2012 and 2014 and between 2015 and 2019.
Alcohol-based hand-rub consumption increased progressively from 2015 to 2019
about 3.6% per year (average consumption 15.1 L/1000 OBDs). Overall antibiotic use in
the hospital during the study years increased from 95 DDD/1000 OBDs in 2012–2014 to
106 in 2015–2019.
3. Discussion
The implementation of our ASP improved the prescription of carbapenems and
decreased their consumption, without negative impact on patient safety. The acceptance
of the intervention made by infectious diseases physician decreased days of treatment,
inpatients days, and the incidence of candidemia and hospital-acquired BSIs caused by
MDR bacteria, despite having increased somewhat the consumption of other antibiotics
that have a lower ecological impact.
The care of patients with suspected infections is complex and metrics to assess ASP
impact are poorly defined [20,21]. Though shorter in their extension, other studies reported
briefer hospital stays with no difference in mortality [8,22], or reported decrease in antimi-
crobial resistance patterns [9,23]. There are no prospective studies outside the ICUs that
analyze the development of infection caused by yeast during antibiotic treatment, and only
two prospective studies refer to readmissions after discharging, without differences be-
tween patients with or without acceptance of ASP recommendation [24,25]. A study carried
out in a carbapenem-resistant Klebsiella pneumoniae endemic hospital showed a decrease in
antibiotics consumption without changes in candidemia or consumption of antifungal [26].
The incidence of Clostridioides difficile-associated diarrhea in our hospital is low and
remained stable, and our results show a decrease in the incidence of hospital-acquired
candidemia and MDR BSIs; this decrease was parallel to the decrease in meropenem
consumption and to the decrease in the days of all antibiotic treatment. Candidemia is the
fourth cause (4.9%) of hospital-acquired BSIs in our hospital. The decrease in the duration
of all antibiotic treatments, the increase in de-escalation from carbapenems to narrower-
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spectrum antibiotics and the lesser development of colonization caused by yeast in patients
in whom the intervention was accepted, have all undoubtedly contributed to the decrease
in candidemia and the consumption of antifungals, without having carried out a direct
intervention on the adequate use of antifungals as in other hospitals [27]. The decrease in
the incidence of yeast infection has occurred despite the increase in the number of surgical
interventions and the increase of intravascular catheter-associated BSIs, with similar use
of parenteral nutrition throughout the study period [28]. Our results are reinforced by a
recent study that shows, on a multivariate analysis, that the treatment of patients with
carbapenems was associated with candidemia, adding weight to antimicrobial stewardship
efforts and restriction of the use of these broad-spectrum antibiotics [15].
The antimicrobial stewardship programs are underfunded and it is necessary to
prioritize those interventions that may have a greater impact [29,30]. We decided to follow
the use of carbapenems because they are the antibiotics with the broadest antibacterial
spectrum and with a rapid induction of beta-lactamases. We have decreased the incidence
of candidemia and hospital-acquired MDR BSIs, and associated mortality, despite the
increases in the total incidence of bacteremia and global consumption of antibiotics.
Understanding the relationship between antibiotic use and antibiotic resistance is
therefore critical for the design of a rational antibiotic stewardship strategy. Because antibi-
otic use is uneven, total use does not distinguish between broad use-many people receiving
a few prescriptions- and intensive use, a few people receiving many prescriptions [31]. It is
necessary to focus on those antibiotics with the most ecological impact to try to reach an
appropriate level of antibiotic use [32,33]. The decrease in the consumption of meropenem
was associated with a slight increase in the consumption of piperacillin-tazobactam and
cefepime, which may have less ecological impact as they are less AmpC inducers [34,35],
and a slight increase in third-generation cephalosporins, aminoglycosides and ertapenem.
The increase in ertapenem consumption may be due to its use to treat ESBL-producing
Enterobacteriaceae infections, at the patient’s hospital discharge.
The results obtained in our study are undoubtedly due to the good acceptance of the
interventions by the prescribers, higher than 42.3% for persuasive interventions described
in the literature [36]. The intervention rejection level it seemed to be more in relation
with clinicians’ attitudes in different hospitalization units and is not associated with the
severity or comorbidity of the patient, according to our previously published results [18].
The decrease in meropenem consumption does not appear to be related to demographic
changes and it is not justified by a decrease in the indications for use, because the incidence
of sepsis and ESBL infections has not decreased, nor does it appear to be related to changes
in the information of pharmaceutical companies, since the use of new antibiotics did
not increase.
The strength of our study is the large number of variables analyzed and prospective
data collection over 5 years to evaluate the impact of ASP, in a community hospital (medium
size) without endemicity of carbapenemase-producing Enterobacteriaceae. We assessed com-
pliance with local guidelines as the standard for appropriate therapy to reduce the more
subjective method of expert opinion-based definitions. We implement prospective audit
with intervention and feedback, which is the mainstay of antimicrobial administration in
the patient setting and is currently recommended based on evidence largely generated in
studies conducted in large tertiary care hospitals. Community hospitals provide most of the
medical care in some countries, but due to their characteristics and limited resources, there
are few long-term studies in these centers on auditing and feedback of carbapenem admin-
istration [37,38]. Our study can be replicated in the hospitals where targeting a specific
antibiotic is needed and an infectious diseases physician is available for intervention.
Our study has several limitations. The study was extended to the entire hospital except
ICU, but the candidemia and MDR BSIs acquired in ICU between 2012and 2019 accounted
for 6.6% of hospital-acquired bacteremia, without significant differences between pre and
post intervention period, and we believe that the activity of this service has not influenced
our results.
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The sample size does not allow use an interrupted time series regression to provide
good stability to the results obtained for all the variables analyzed, but they reflect the
changes in consumption of meropenem and in the incidence of hospital-acquired can-
didemia and MDR BSIs, after starting the ASP. Meropenem consumption level drop from
50.5 DDD/1000 OBDs in 2014 to 35.2 in 2015 coinciding with the start-up of ASP, and
consumption has remained lower throughout the intervention period. This change in trend
seem to be due to our intervention and not to changes in healthcare during the study period.
As an ecologic study, it depicts association and not causal relations, because antibiotic
resistance is temporally dynamic. Further work is needed to distinguish between different
causal pathways [39].
The single-center design limits the possibility of generalizing our results to other
hospitals, and including preferred methods, such as control groups or randomization was
impractical. Although the complexity of hospitals and infection prevention and control
policies may be different, it should be noted that in last five years carbapenem-resistant
Klebsiella pneumoniae and Pseudomonas aeruginosa, and MRSA is lower in our hospital than
in the rest of the hospitals in our geographical area [40].
4. Materials and Methods
This study is part of a larger assessment and the detailed description of the procedure
has already been previously reported elsewhere and is briefly described below.
At the end of 2014, a team of professionals was constituted for ASP implementation,
local guidelines for empiric antibiotic treatment were developed, and between January
2015 and December 2019, a prospective follow-up of carbapenems use was performed.
We analyzed the evolution of adequacy of carbapenems prescription to local guidelines
and clinical impact, antibiotic consumption and the incidence of bloodstream infections
acquired in the hospital.
A descriptive study pre-post-intervention was conducted between January 2012 and
December 2019.
The study was conducted in a 350-bed teaching hospital without endemicity of
carbapenemase-producing Enterobacteriaceae, located in Galicia (autonomous commu-
nity of northwest of Spain). The hospital has one ICU with 10 beds and does not have
transplant programs.
The infection prevention and control program was the same throughout the study.
From 2012, an infectious diseases physician performed prospective active surveillance of
all episodes of bloodstream infections (BSIs) [41].
Interventions:
Patients who started treatment with carbapenems available in our hospital (meropenem
and ertapenem) were identified every day throughout the 5 years using a drug dispen-
sation program (all hospital units, except ICU). Prescriber counselling measures were
performed the first day of prescription, and annual training on optimization of antibiotic
use was carried out for the first 3 years, targeting trainee pharmacists and physicians. An
annual antimicrobial stewardship program update was presented at a hospital general
clinical session.
An infectious diseases physician was released 6 h a week to perform active surveil-
lance. For each case, the electronic medical record was reviewed by infectious diseases
physician and antibiotic treatment recommendations to prescribers were given, on a face-to-
face or telephone conversation basis, or through an electronic medical record. Additional
differential diagnoses, investigations, and adjunctive therapy (for example, removal of
urinary or central venous catheters, and drainage of infected collections) were also recom-
mended. Adherence to, or rejection of the recommendations were reviewed by an infectious
diseases physician 24 and 48 h post-recommendation, as part of the ASP workflow. Data
were obtained by monitoring the information recorded in the electronic medical record.
Prospective and protocolized information was collected for each case [18]. This study was
approved by the Institutional Review Boards and Ethics Committee.
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4.1. Adequacy of Treatment
Appropriate treatment with carbapenems was considered when it was prescribed in
patients with: (1) severe sepsis [42]; (2) history of ESBLs colonization; or (3) hospital-acquired
infection in which a broad-spectrum antibiotic treatment was considered necessary.
4.2. Clinical Impact
In cases in which carbapenem treatment was not justified during 2015–2019, a com-
parison was made between the cases with accepted intervention and cases with rejected
intervention in their clinical outcome, days of antibiotic treatment, collateral damage
(development of phlebitis, resistance to treatment, diarrhea caused by C. difficile, or for
colonization-infection with Candida spp.), inpatient days, and hospital readmission. All-
cause mortality was defined over one month of follow-up; 30-day infection-related and
all-cause readmission were defined as readmission occurring within 30 days after discharge
from current admission. During the study period, antibiotic consumption was assessed as
defined daily doses (DDD) per 1000 occupied bed days (OBDs) [43]. The impact on the use
of antibiotics was made comparing the DDD/1000 OBDs between the years 2012 and 2019.
4.3. Impact on Resistance
We analyzed, between January 2012 and December 2019, the evolution of incidence
density per 1000 OBDs of hospital-acquired BSIs produced by the most frequently isolated
bacteria and by Candida spp.
Hospital-acquired BSIs were defined as those diagnosed from blood cultures obtained
≥48 h after hospital admission or in those cases when, even occurring in the first 48 h,
the patient had been hospitalized during the previous two weeks.
The identification of blood isolates and the determination of resistance to antibiotics
were performed according to Clinical Laboratory Standard International (CLSI). The MDR
categorization was applied for ESBLs or carbapenemase-producing Enterobacteriaceae, all
isolates of methicillin-resistant Staphylococcus aureus (MRSA), and all Pseudomonas aerug-
inosa and Acinetobacter baumannii strains fulfilling the German Society for Hygiene and
Microbiology criteria for MDR organisms [44]. Colonization was defined as the isolation of
the organism from a non-sterile site in the absence of symptoms, and infection when the
patient’s doctor prescribed treatment.
4.4. Statistical Analysis
A descriptive and comparative study of the variables was performed. Quantitative
variables are reported as means ± standard deviations, and categorical as frequencies
(%). Variables were compared between groups using Chi-square test or Fisher exact test
for categorical variables, Student t-test, or Mann–Whitney U for continuous variables,
as appropriate. Associations between the variables were expressed as odds ratios (ORs)
and 95% confidence intervals (CIs). Antibiotic consumption (DDD per 1000 occupied bed
days), resistance rates per 1000 OBDs of hospital acquired BSIs with a 95%CI and rates of
mortality were calculated as Poisson event rates, and compared by testing for homogeneity
of rates. Statistical analysis was performed using SPSS software version 19. All tests were
2-tailed; a p value < 0.05 was regarded as statistically significant.
An interrupted time-series analysis was performed to verify any significant change
in antibiotic consumption line; we used the Joinpoint Regression Program 4.5.0.1 to run
the calculations.
5. Conclusions
The results of this study show that the decrease and better use of carbapenems
achieved by our stewardship program could have a sustained clinical and ecological
impact over five years, reducing inpatient days and incidence of hospital-acquired MDR
BSIs and candidemia, despite the increase in consumption of other antibiotics with less
impact on the microbiome.
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